However, when BIX-01294 is used in cancer cells, loss of G9A function leads to reduced H3K9 methylation on the promoters of these genes, allowing the chromatin to become accessible and the previously silenced genes to become responsive to transcriptional regulation. The gene discussed is EHMT2; the disease is cancer.